OR WAIT null SECS
September 17, 2021
Apellis Pharmaceuticals has announced the top-line results from two Phase III studies, evaluating intravitreal pegcetacoplan as a treatment for geographic atrophy.
Exscientia has entered into a four-year agreement with the Bill & Melinda Gates Foundation for the development of small-molecule therapeutics that can tackle coronavirus and other viruses with pandemic potential.
September 16, 2021
FDA and EMA will provide scientific advice to applicants concerning complex generic and hybrid products.
September 14, 2021
Both Marion Gruber and Phillip Krause, FDA officials, co-authored a document disputing the need for COVID-19 boosters for most people.
September 10, 2021
ABPI has announced that eight leaders from the patient and health charity sector have been chosen to join its new Patient Advisory Council.
NICE has reconsidered its decision on Janssen's Erleada (apalutamide), issuing two positive final appraisal determinations (FADs) on the therapy.
NICE has recommended tofacitinib (Xeljanz, Pfizer)as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis.
Sterling Pharma Solutions has invested in a center of excellence for research into commercial applications of continuous flow chemistry at its site in Dudley, UK.
Nanoform and Herantis Pharma's proof of concept project evaluating the application of the nanoforming process has been successful.
The White House announced a nearly $3 billion program to ramp up production of vaccines and their components.